Patents by Inventor Ming Bo Huang

Ming Bo Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING AIDS OR CANCER BY INHIBITING THE SECRETION OF MICROPARTICLES
    Publication number: 20130018002
    Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.
    Type: Application
    Filed: September 17, 2012
    Publication date: January 17, 2013
    Applicant: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
  • COMPOSITIONS AND METHODS FOR TREATING AIDS OR CANCER BY INHIBITING THE SECRETION OF MICROPARTICLES
    Publication number: 20130018003
    Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.
    Type: Application
    Filed: September 17, 2012
    Publication date: January 17, 2013
    Applicant: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
  • Tumor cytotoxicity induced by modulators of the CXCR4 receptor
    Patent number: 7960346
    Abstract: The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: June 14, 2011
    Assignee: Morehouse School of Medicine
    Inventors: Vincent C. Bond, James W. Lillard, Ming Bo Huang, Harvey Bumpers, Michael Powell
  • Methods of generating a humoral immune response against human immunodeficiency virus (HIV) comprising administering Nef apoptotic motif-containing polypeptide-conjugates
    Patent number: 7943139
    Abstract: A small peptide of 10 or 11 mers, when linked to an immunogenic moiety, can protect against naferious effects of Nef protein of HIV. The vaccine is not used to induce sterilizing immunity, but to block the ability of soluble Nef protein to induce apoptosis, and to therefore alleviate lymphocyte depletion and organ damage.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: May 17, 2011
    Assignee: Morehouse School of Medicine
    Inventors: Vincent C. Bond, Michael Powel, Ming Bo Huang, Cleve James
  • COMPOSITIONS AND METHODS FOR TREATING AIDS OR CANCER BY INHIBITING THE SECRETION OF MICROPARTICLES
    Publication number: 20100317566
    Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.
    Type: Application
    Filed: May 20, 2010
    Publication date: December 16, 2010
    Applicant: Morehouse School of Medicine
    Inventors: Vincent Craig BOND, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
  • Tumor cytotoxicity induced by modulators of the CXCR4 receptor
    Publication number: 20080227720
    Abstract: The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form.
    Type: Application
    Filed: November 5, 2007
    Publication date: September 18, 2008
    Inventors: Vincent C. Bond, James W. Lillard, Ming Bo Huang, Harvey Bumpers, Michael Powell
  • Tumor cytotoxicity induced by modulators of the CXCR4 receptor
    Patent number: 7312305
    Abstract: The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form.
    Type: Grant
    Filed: March 20, 2003
    Date of Patent: December 25, 2007
    Assignee: Morehouse School of Medicine
    Inventors: Vincent C. Bond, James Lillard, Ming Bo Huang, Harvey Bumpers, Michael Powell
  • Tumor cytotoxicity induced by modulators of the CXCR4 receptor
    Publication number: 20040037825
    Abstract: The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form.
    Type: Application
    Filed: March 20, 2003
    Publication date: February 26, 2004
    Inventors: Vincent C. Bond, James W. Lillard, Ming Bo Huang, Harvey Bumpers, Michael Powell